BPA for cinryze, kalbitor, takhzyro, elaprase, vpriv, firazyr, adzynma, livtencity, and gattex.
Ended Awarded Last action
- Contract number
- 36E79725A0016
- Awardee
-
Takeda Pharmaceuticals America, Inc. UEI DDEVYUAXJ624
- Awarding agency
-
National Acquisition Center
Headquarters, Department of Veterans Affairs
- Task orders
- 0
Award facts
- Opportunity
-
- VA797P12Q0002 Solicitation number
- Last date to order 100% complete
- IDV ceiling
- $131,039,520.00
- Award type
- Single award
- Who can order
- Only the awarding agency
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 1 offer Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
Award details come from SAM.gov/FPDS.
About this IDV
Takeda Pharmaceuticals America Inc. has been awarded a single-award Blanket Purchase Agreement (BPA) by the Department of Veterans Affairs National Acquisition Center for specialized pharmaceutical products valued at $131.0 million, effective July 15, 2025, through March 12, 2026. This child contract operates under the General Services Administration (GSA) Pharmaceuticals and Drugs Schedule (FSS-61-IB) and covers nine therapeutic agents: CINRYZE, KALBITOR, TAKHZYRO, ELAPRASE, VPRIV, FIRAZYR, ADZYNMA, LIVTENCITY, and GATTEX. The BPA was issued without set-aside designation, reflecting the specialized and often single-source nature of these biopharmaceutical products. These medications address complex medical conditions including hereditary angioedema, hemophilia, immune disorders, rare genetic metabolic disorders, and short bowel syndrome, serving veteran and federal beneficiary populations across multiple therapeutic areas.
The BPA structure streamlines procurement of these advanced pharmaceutical interventions through delivery orders issued by Veterans Integrated Service Networks and other authorized federal healthcare agencies, enabling rapid procurement without individual competitive procurements while maintaining pre-negotiated pricing terms and provisions for 2026 Public Law pricing updates. As a foreign-owned subsidiary of Japan-based Takeda Pharmaceutical Company Limited, the prime contractor operates from Lexington, Massachusetts and maintains established relationships as a critical supplier across Department of Veterans Affairs facilities, the Department of Justice Bureau of Prisons, and other federal healthcare entities. This BPA consolidates procurement for highly specialized medications essential to federal healthcare operations, reducing administrative burden and lead times while ensuring consistent access to these therapeutically critical products for eligible federal beneficiaries.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Legal Contract Cancellation | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Original award | $0 |
Quick answers
Who was awarded contract 36E79725A0016?
36E79725A0016 was awarded to Takeda Pharmaceuticals America, Inc. by National Acquisition Center (Headquarters) on July 15, 2025.
How much is contract 36E79725A0016 worth?
36E79725A0016's own ceiling is $131,039,520.
Who can order from contract 36E79725A0016?
36E79725A0016 is a single award blanket purchase agreement. Only the awarding agency can place orders on it.
Is contract 36E79725A0016 under another contract?
Yes. 36E79725A0016 is a blanket purchase agreement under V797D50492, a federal supply schedule, on Pharmaceuticals and Drugs (FSS-61-IB).
Was contract 36E79725A0016 competed?
The extent of competition for 36E79725A0016 was full and open competition. The government received 1 offer.
On GovTribe
See this IDV's full record
- Every order and transaction
- The awardee's other awards and teaming partners
- Similar IDVs and recompete opportunities
- Ask GovTribe AI about this IDV